Publications by authors named "Robert J Massey"
Background: BMI variability has been associated with increased cardiovascular disease risk in individuals with type 2 diabetes, however comparison between clinical studies and real-world observational evidence has been lacking. Furthermore, it is not known whether BMI variability has an effect independent of HbA1c variability.
Methods: We investigated the association between BMI variability and 3P-MACE risk in the Harmony Outcomes trial (n = 9198), and further analysed placebo arms of REWIND (n = 4440) and EMPA-REG OUTCOME (n = 2333) trials, followed by real-world data from the Tayside Bioresource (n = 6980) using Cox regression modelling.
Article Synopsis
- A systematic review was conducted to explore the relationship between clinical and biological features and the effectiveness of two diabetes treatments: SGLT2-inhibitors and GLP1-receptor agonists, focusing on outcomes like glycaemic control, cardiovascular health, and kidney function.
- Out of over 5,600 studies screened, only 101 for SGLT2-inhibitors and 75 for GLP1-receptor agonists were included, but many had methodological flaws that limited their reliability in assessing how different patients react to these treatments.
- Findings suggest that factors like lower kidney function and reduced insulin secretion could affect treatment responses, but overall evidence is weak; further well-designed studies are needed to better understand treatment diversity and enhance
Background: A precision medicine approach in type 2 diabetes requires identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity could support more individualized clinical decisions on optimal type 2 diabetes therapy.
Methods: We performed a pre-registered systematic review of meta-analysis studies, randomized control trials, and observational studies evaluating clinical and biological features associated with heterogenous treatment effects for SGLT2-inhibitor and GLP1-receptor agonist therapies, considering glycaemic, cardiovascular, and renal outcomes.
The association between body weight variability and the risk of cardiovascular disease (CVD) has been investigated previously with mixed findings. However, there has been no extensive study which systematically evaluates the current evidence. Furthermore, the impact of ethnicity and type 2 diabetes on this phenomena has not yet been investigated.
View Article and Find Full Text PDF